Entrectinib (RXDX-101), a TRKA/B/C, ROS1, and ALK inhibitor, is being studied in a phase I/II trial (NCT02650401) recruiting children and young adults with recurrent/refractory CNS tumors harboring NTRK1/2/3, ROS1, and ALK molecular alterations, as confirmed by a CLIA-approved lab. This evidence concerns the gene ROS1 and central nervous system neoplasm.